A61K 38/482
Serine endopeptidases
Official title: {Serine endopeptidases (3.4.21)}
A61K38/482 (Serine endopeptidases) appears on 1,535 US grants and 2,761 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,535
- Published applications
- 2,761
- Assignees
- 986
- Inventors
- 3,459
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 4 | 0 |
| 1978 | 0 | 0 |
| 1979 | 3 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 1 | 0 |
| 1984 | 11 | 0 |
| 1985 | 4 | 0 |
| 1986 | 3 | 0 |
| 1987 | 3 | 0 |
| 1988 | 3 | 0 |
| 1989 | 2 | 0 |
| 1990 | 2 | 0 |
| 1991 | 1 | 0 |
| 1992 | 5 | 0 |
| 1993 | 2 | 0 |
| 1994 | 4 | 0 |
| 1995 | 3 | 0 |
| 1996 | 9 | 0 |
| 1997 | 11 | 0 |
| 1998 | 19 | 0 |
| 1999 | 23 | 0 |
| 2000 | 24 | 0 |
| 2001 | 23 | 13 |
| 2002 | 24 | 49 |
| 2003 | 16 | 91 |
| 2004 | 16 | 74 |
| 2005 | 28 | 88 |
| 2006 | 30 | 91 |
| 2007 | 33 | 93 |
| 2008 | 32 | 112 |
| 2009 | 30 | 87 |
| 2010 | 30 | 128 |
| 2011 | 47 | 116 |
| 2012 | 59 | 110 |
| 2013 | 77 | 138 |
| 2014 | 85 | 166 |
| 2015 | 99 | 153 |
| 2016 | 78 | 165 |
| 2017 | 100 | 142 |
| 2018 | 89 | 130 |
| 2019 | 96 | 172 |
| 2020 | 87 | 124 |
| 2021 | 72 | 113 |
| 2022 | 65 | 93 |
| 2023 | 43 | 101 |
| 2024 | 59 | 89 |
| 2025 | 52 | 66 |
| 2026 | 25 | 57 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods of treating ischemic disease by administering an ATR kinase inhibitor22 Sep 2026US 12,740,980 B2East Tennessee State University Research Foundation
- Method and medicine for treating Huntington's disease15 Sep 2026US 12,734,222 B2Talengen International Limited
- Composition for kidney treatment using omentum, a medical kit for kidney treatment, including the same, and film for kidney treatment, including cured product thereof21 Jul 2026US 12,685,752 B2Rokit Healthcare Inc.
- Methods for treating intracranial hemorrhage and assessing efficacy21 Jul 2026US 12,685,763 B2Alexion Pharmaceuticals, Inc.
- Factor IX polypeptide formulations16 Jun 2026US 12,653,871 B2Bioverativ Therapeutics Inc.
- Plasmin-induced internal limiting membrane digestion facilitates donor retinal ganglion cell transplantation8 Oct 2026US 2026/0306549 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Human factor vii deletion constructs for treating cancer8 Oct 2026US 2026/0306592 A1The Cleveland Clinic Foundation
- Combined use of bispecific antibody binding to activated coagulation factor ix and coagulation factor x with blood coagulation factor x for treating subject with hemophilia a1 Oct 2026US 2026/0295022 A1KM Biologics Co., Ltd.
- Compositions and Methods for Treating Celiac Sprue Disease24 Sep 2026US 2026/0284156 A1University of Washington Through Its Center For Commercializaiton
- Powder composition comprising a haemostatic agent24 Sep 2026US 2026/0284157 A1Centre National De La Recherche Scientifique
Most cited
By later US patents
- Non-immunogenic polypeptides2,007US 4,179,337 A1979
- Supplemented and unsupplemented tissue sealants, methods of their production and use441US 6,197,325 B1American National Red Cross · 2001
- Lipid formulation340US 8,158,601 B2Alnylam Pharmaceuticals, Inc. · 2012
- Medical implants and fibrosis-inducing agents330US 7,166,570 B2Angiotech International AG · 2007
- Engineered nucleic acids encoding a modified erythropoietin and their expression312US 8,710,200 B2Moderna Therapeutics, Inc. · 2014